Wire · founder news, decoded · opportunities
FDA final guidance on psychedelics opens the door to psycho-oncology research
FDA released final guidance for psychedelic drug trials (psilocybin, LSD, MDMA) in psychiatric and substance abuse disorders, permitting treatment without mandatory psychotherapy—a regulatory shift that opens psycho-oncology research pathways.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
If you're running psychedelic trials for cancer patients, you no longer need to build psychotherapy into your protocol—FDA just cut a regulatory cost and complexity barrier that was keeping smaller teams out. The door to psycho-oncology is now open; the question is which established oncology player moves first.
Read the full story at cancerletter.com →
Topics: Digital Health · psychedelics · clinical-trials · fda-guidance · psycho-oncology · psychiatric-treatment